DK1257281T3 - Nukleosidanaloger med carboxamidin-modificeret monocyklisk base - Google Patents

Nukleosidanaloger med carboxamidin-modificeret monocyklisk base

Info

Publication number: DK1257281T3
Authority: DK; Denmark
Prior art keywords: carboxamidine; nucleoside analogs; monocyclic base; modified; modified monocyclic
Prior art date: 2000-02-15

Application number

DK01920996T

Other languages

English (en)

Inventor

Robert Tam

Kanda Ramasamy

Zhi Hong

Johnson Lau

Original Assignee

Valeant Pharmaceuticals North

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-15

Filing date

2001-02-15

Publication date

2008-01-14

2001-02-15 Application filed by Valeant Pharmaceuticals North filed Critical Valeant Pharmaceuticals North

2008-01-14 Application granted granted Critical

2008-01-14 Publication of DK1257281T3 publication Critical patent/DK1257281T3/da

Links

125000002950 monocyclic group Chemical group 0.000 title 1
239000002777 nucleoside Substances 0.000 title 1
150000003833 nucleoside derivatives Chemical class 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 2
208000036142 Viral infection Diseases 0.000 abstract 2
230000009385 viral infection Effects 0.000 abstract 2
241000700721 Hepatitis B virus Species 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Obesity (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)

DK01920996T 2000-02-15 2001-02-15 Nukleosidanaloger med carboxamidin-modificeret monocyklisk base DK1257281T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US18267600P	2000-02-15	2000-02-15
US09/595,365 US6455508B1 (en)	2000-02-15	2000-10-05	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
PCT/US2001/040148 WO2001060379A1 (en)	2000-02-15	2001-02-15	Nucleoside analogs with carboxamidine modified monocyclic base

Publications (1)

Publication Number	Publication Date
DK1257281T3 true DK1257281T3 (da)	2008-01-14

Family

ID=26878297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01920996T DK1257281T3 (da)	2000-02-15	2001-02-15	Nukleosidanaloger med carboxamidin-modificeret monocyklisk base

Country Status (28)

Country	Link
US (1)	US6455508B1 (da)
EP (3)	EP1813278B9 (da)
JP (3)	JP4975930B2 (da)
KR (2)	KR100811927B1 (da)
CN (2)	CN1268335C (da)
AT (1)	ATE377422T1 (da)
AU (2)	AU783142B2 (da)
BR (2)	BR0108401A (da)
CA (2)	CA2395854A1 (da)
CY (1)	CY1107103T1 (da)
CZ (2)	CZ302327B6 (da)
DE (1)	DE60131250T8 (da)
DK (1)	DK1257281T3 (da)
ES (2)	ES2295148T3 (da)
HR (2)	HRP20020583A2 (da)
HU (2)	HU229480B1 (da)
IL (3)	IL150555A0 (da)
MX (2)	MXPA02007932A (da)
NO (2)	NO329927B1 (da)
NZ (2)	NZ521390A (da)
PL (2)	PL365239A1 (da)
PT (1)	PT1257281E (da)
RS (1)	RS20090086A (da)
RU (2)	RU2259831C2 (da)
SI (2)	SI21077A (da)
SK (2)	SK287765B6 (da)
WO (2)	WO2001060379A1 (da)
YU (1)	YU61502A (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6831069B2 (en) *	1999-08-27	2004-12-14	Ribapharm Inc.	Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7638496B2 (en) *	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
US7056895B2 (en) *	2000-02-15	2006-06-06	Valeant Pharmaceuticals International	Tirazole nucleoside analogs and methods for using same
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
KR20080021797A (ko)	2000-05-26	2008-03-07	이데닉스(케이만)리미티드	플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
WO2002057425A2 (en)	2001-01-22	2002-07-25	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003037908A1 (en) *	2001-10-31	2003-05-08	Ribapharm Inc.	Antiviral combination therapy and compositions
NZ537662A (en)	2002-06-28	2007-10-26	Idenix Cayman Ltd	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL374781A1 (en)	2002-06-28	2005-10-31	Idenix (Cayman) Limited	2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
HUE033832T2 (en)	2002-11-15	2018-01-29	Idenix Pharmaceuticals Llc	2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
RU2005121904A (ru)	2002-12-12	2006-01-20	Айденикс (Кайман) Лимитед (Ky)	Способ получения 2`-разветвленных нуклеозидов
RU2005133093A (ru) *	2003-03-28	2006-07-27	Фармассет, Инк. (Us)	Соединения для лечения флавивирусных инфекций
US20040197292A1 (en) *	2003-04-04	2004-10-07	The Procter & Gamble Company	Personal care composition containing an antidandruff component and a nonionic surfactant
US20040202636A1 (en) *	2003-04-11	2004-10-14	Kaczvinsky Joseph Robert	Personal care composition containing an antidandruff component and a nonionic surfactant
US20040197287A1 (en) *	2003-04-04	2004-10-07	The Procter & Gamble Company	Personal care composition containing an antidandruff component and a nonionic surfactant
US6930093B2 (en) *	2003-07-10	2005-08-16	Valeant Research & Development	Use of ribofuranose derivatives against inflammatory bowel diseases
US20050009848A1 (en) *	2003-07-10	2005-01-13	Icn Pharmaceuticals Switzerland Ltd.	Use of antivirals against inflammatory bowel diseases
WO2005018330A1 (en) *	2003-08-18	2005-03-03	Pharmasset, Inc.	Dosing regimen for flaviviridae therapy
US20050095218A1 (en) *	2003-10-29	2005-05-05	The Procter & Gamble Company	Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
AU2005254057B2 (en)	2004-06-15	2011-02-17	Isis Pharmaceuticals, Inc.	C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
CA2606195C (en)	2005-05-02	2015-03-31	Merck And Co., Inc.	Hcv ns3 protease inhibitors
AR057456A1 (es)	2005-07-20	2007-12-05	Merck & Co Inc	Inhibidores de la proteasa ns3 del vhc
NZ565269A (en)	2005-08-01	2010-03-26	Merck & Co Inc	Macrocyclic peptides as HCV NS3 protease inhibitors
EP1976382B1 (en)	2005-12-23	2013-04-24	IDENIX Pharmaceuticals, Inc.	Process for preparing a synthetic intermediate for preparation of branched nucleosides
US8497292B2 (en)	2005-12-28	2013-07-30	Translational Therapeutics, Inc.	Translational dysfunction based therapeutics
WO2007123579A2 (en) *	2005-12-28	2007-11-01	Translational Therapeutics	Translational dysfunction based therapeutics
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
WO2008005542A2 (en) *	2006-07-07	2008-01-10	Gilead Sciences, Inc.,	Antiviral phosphinate compounds
AU2007309488B2 (en)	2006-10-24	2012-10-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
CA2667146C (en)	2006-10-24	2016-01-19	Merck & Co., Inc.	Hcv ns3 protease inhibitors
AU2007309546A1 (en)	2006-10-24	2008-05-02	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	HCV NS3 protease inhibitors
BRPI0718161A2 (pt)	2006-10-27	2013-11-26	Merck & Co Inc	Composto, composição farmacêutica, e, uso do composto.
US8377874B2 (en)	2006-10-27	2013-02-19	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
GB0625345D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
CA2672250C (en)	2006-12-20	2013-04-30	Ian Stansfield	Antiviral indoles
GB0625349D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
JP2010533699A (ja)	2007-07-17	2010-10-28	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	Ｃ型肝炎感染症の治療のための大環状インドール誘導体
AU2008277377B2 (en)	2007-07-19	2013-08-01	Msd Italia S.R.L.	Macrocyclic compounds as antiviral agents
WO2009134624A1 (en)	2008-04-28	2009-11-05	Merck & Co., Inc.	Hcv ns3 protease inhibitors
EA019327B1 (ru)	2008-07-22	2014-02-28	Мерк Шарп Энд Домэ Корп.	Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
WO2010082050A1 (en)	2009-01-16	2010-07-22	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en)	2009-01-20	2009-03-04	Angeletti P Ist Richerche Bio	Antiviral agents
US8828930B2 (en)	2009-07-30	2014-09-09	Merck Sharp & Dohme Corp.	Hepatitis C virus NS3 protease inhibitors
EP2780026B1 (en)	2011-11-15	2019-10-23	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
WO2013106344A1 (en)	2012-01-12	2013-07-18	Ligand Pharmaceuticals, Inc.	2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
CN102978264B (zh) *	2012-11-14	2014-12-10	广东肇庆星湖生物科技股份有限公司	一种他立韦林的制备方法
WO2014121418A1 (en)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
JP2017512183A (ja)	2014-02-13	2017-05-18	リガンド・ファーマシューティカルズ・インコーポレイテッド	プロドラッグ化合物およびそれらの使用
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
EA201890454A1 (ru) *	2015-08-06	2018-07-31	Чимерикс, Инк.	Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
WO2019060692A1 (en)	2017-09-21	2019-03-28	Chimerix, Inc.	MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
RU2020126177A (ru)	2018-01-09	2022-02-10	Лиганд Фармасьютикалз, Инк.	Ацетальные соединения и их терапевтическое применение

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3984396A (en)	1971-06-01	1976-10-05	Icn Pharmaceuticals, Inc.	1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3798209A (en)	1971-06-01	1974-03-19	Icn Pharmaceuticals	1,2,4-triazole nucleosides
US3991078A (en)	1971-06-01	1976-11-09	Icn Pharmaceuticals, Inc.	N-substituted 1,2,4-triazoles
USRE29835E (en)	1971-06-01	1978-11-14	Icn Pharmaceuticals	1,2,4-Triazole nucleosides
US3962211A (en) *	1975-01-13	1976-06-08	The University Of Utah	7-substituted nucleoside compounds
US4093624A (en)	1977-01-31	1978-06-06	Icn Pharmaceuticals, Inc.	1,2,4-Thiadiazolidine-3,5-dione
SU1124559A1 (ru) *	1983-06-08	1986-07-07	Институт молекулярной биологии АН СССР	1-(2-Оксиэтоксиметил)-1,2,4-триазол-5-карбоксамид,обладающий активностью противвируса герпеса
JPS6426593A (en)	1987-07-21	1989-01-27	Asahi Glass Co Ltd	Nucleoside derivative
US4892865A (en) *	1987-12-01	1990-01-09	The Regents Of The University Of Michigan	Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5405837A (en) *	1993-05-18	1995-04-11	Indiana University Foundation	Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
RU2186569C2 (ru) *	1996-01-23	2002-08-10	Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ	Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
IL129126A0 (en) *	1996-10-16	2000-02-17	Icn Pharmaceuticals	Monocyclic l-nucleosides analogs and uses thereof
WO2001027114A1 (en) *	1999-08-27	2001-04-19	Icn Pharmaceuticals, Inc.	PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS

2000
- 2000-10-05 US US09/595,365 patent/US6455508B1/en not_active Expired - Lifetime
2001
- 2001-02-15 JP JP2001559475A patent/JP4975930B2/ja not_active Expired - Fee Related
- 2001-02-15 WO PCT/US2001/040148 patent/WO2001060379A1/en not_active Ceased
- 2001-02-15 IL IL15055501A patent/IL150555A0/xx unknown
- 2001-02-15 JP JP2001559477A patent/JP2004510691A/ja active Pending
- 2001-02-15 NZ NZ521390A patent/NZ521390A/en unknown
- 2001-02-15 YU YU61502A patent/YU61502A/sh unknown
- 2001-02-15 AU AU47988/01A patent/AU783142B2/en not_active Ceased
- 2001-02-15 RS RSP-2009/0086A patent/RS20090086A/sr unknown
- 2001-02-15 HU HU0300027A patent/HU229480B1/hu unknown
- 2001-02-15 IL IL15099001A patent/IL150990A0/xx unknown
- 2001-02-15 BR BR0108401-1A patent/BR0108401A/pt not_active IP Right Cessation
- 2001-02-15 SI SI200120011A patent/SI21077A/sl not_active IP Right Cessation
- 2001-02-15 MX MXPA02007932A patent/MXPA02007932A/es unknown
- 2001-02-15 SK SK1149-2002A patent/SK287765B6/sk not_active IP Right Cessation
- 2001-02-15 AU AU38450/01A patent/AU3845001A/en not_active Abandoned
- 2001-02-15 EP EP07107588.1A patent/EP1813278B9/en not_active Expired - Lifetime
- 2001-02-15 RU RU2002120922/15A patent/RU2259831C2/ru active
- 2001-02-15 PT PT01920996T patent/PT1257281E/pt unknown
- 2001-02-15 HR HR20020583A patent/HRP20020583A2/xx not_active Application Discontinuation
- 2001-02-15 ES ES01920996T patent/ES2295148T3/es not_active Expired - Lifetime
- 2001-02-15 BR BR0108402-0A patent/BR0108402A/pt not_active Application Discontinuation
- 2001-02-15 CZ CZ20022798A patent/CZ302327B6/cs not_active IP Right Cessation
- 2001-02-15 DK DK01920996T patent/DK1257281T3/da active
- 2001-02-15 MX MXPA02007931A patent/MXPA02007931A/es active IP Right Grant
- 2001-02-15 EP EP01920996A patent/EP1257281B8/en not_active Expired - Lifetime
- 2001-02-15 HU HU0300912A patent/HUP0300912A2/hu unknown
- 2001-02-15 CZ CZ20022799A patent/CZ20022799A3/cs unknown
- 2001-02-15 KR KR1020027010417A patent/KR100811927B1/ko not_active Expired - Fee Related
- 2001-02-15 AT AT01920996T patent/ATE377422T1/de active
- 2001-02-15 EP EP01910892A patent/EP1278528A4/en not_active Withdrawn
- 2001-02-15 KR KR1020027010593A patent/KR20030005190A/ko not_active Withdrawn
- 2001-02-15 SI SI200120010A patent/SI21076A/sl not_active IP Right Cessation
- 2001-02-15 HR HR20020657A patent/HRP20020657A2/hr not_active Application Discontinuation
- 2001-02-15 WO PCT/US2001/005172 patent/WO2001060381A1/en not_active Ceased
- 2001-02-15 CA CA002395854A patent/CA2395854A1/en not_active Abandoned
- 2001-02-15 RU RU2002120483/14A patent/RU2002120483A/ru not_active Application Discontinuation
- 2001-02-15 DE DE60131250T patent/DE60131250T8/de active Active
- 2001-02-15 ES ES07107588.1T patent/ES2528429T3/es not_active Expired - Lifetime
- 2001-02-15 SK SK1157-2002A patent/SK11572002A3/sk unknown
- 2001-02-15 CA CA2399208A patent/CA2399208C/en not_active Expired - Fee Related
- 2001-02-15 NZ NZ52087701A patent/NZ520877A/xx not_active IP Right Cessation
- 2001-02-15 CN CNB018077455A patent/CN1268335C/zh not_active Expired - Fee Related
- 2001-02-15 CN CN01805036A patent/CN1420779A/zh active Pending
- 2001-02-15 PL PL01365239A patent/PL365239A1/xx unknown
- 2001-02-15 PL PL357945A patent/PL200140B1/pl unknown
2002
- 2002-07-30 IL IL150990A patent/IL150990A/en not_active IP Right Cessation
- 2002-08-14 NO NO20023855A patent/NO329927B1/no not_active IP Right Cessation
- 2002-08-14 NO NO20023852A patent/NO20023852L/no not_active Application Discontinuation
2007
- 2007-12-19 CY CY20071101614T patent/CY1107103T1/el unknown
2009
- 2009-01-29 JP JP2009018382A patent/JP5253204B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA02007932A (es)	2004-10-15
CN1438891A (zh)	2003-08-27
IL150555A0 (en)	2003-02-12
CN1268335C (zh)	2006-08-09
ES2528429T9 (es)	2015-05-07
CA2399208A1 (en)	2001-08-23
NO329927B1 (no)	2011-01-24
DE60131250T8 (de)	2009-01-15
KR100811927B1 (ko)	2008-03-10
SI21076A (sl)	2003-06-30
HUP0300912A2 (hu)	2003-08-28
KR20030005190A (ko)	2003-01-17
PL365239A1 (en)	2004-12-27
RU2259831C2 (ru)	2005-09-10
BR0108402A (pt)	2003-03-11
BR0108401A (pt)	2004-01-06
WO2001060381B1 (en)	2001-11-01
NZ520877A (en)	2004-12-24
RU2002120922A (ru)	2004-01-27
HRP20020583A2 (en)	2005-10-31
HRP20020657A2 (en)	2005-10-31
IL150990A0 (en)	2003-02-12
PT1257281E (pt)	2007-12-11
KR20030032917A (ko)	2003-04-26
CZ302327B6 (cs)	2011-03-16
DE60131250D1 (de)	2007-12-20
HK1051149A1 (en)	2003-07-25
AU783142B2 (en)	2005-09-29
WO2001060379A1 (en)	2001-08-23
NO20023852L (no)	2002-10-09
CY1107103T1 (el)	2012-10-24
RS20090086A (sr)	2010-06-30
ATE377422T1 (de)	2007-11-15
WO2001060381A1 (en)	2001-08-23
NO20023852D0 (no)	2002-08-14
CZ20022799A3 (cs)	2003-09-17
JP2009102406A (ja)	2009-05-14
HU229480B1 (en)	2014-01-28
DE60131250T2 (de)	2008-08-28
CZ20022798A3 (cs)	2003-03-12
NO20023855L (no)	2002-10-08
EP1278528A1 (en)	2003-01-29
SI21077A (sl)	2003-06-30
SK11572002A3 (sk)	2003-02-04
AU3845001A (en)	2001-08-27
CA2399208C (en)	2010-04-13
EP1257281A1 (en)	2002-11-20
YU61502A (sh)	2006-03-03
HUP0300027A3 (en)	2003-09-29
SK11492002A3 (sk)	2003-02-04
AU4798801A (en)	2001-08-27
ES2528429T3 (es)	2015-02-09
EP1257281B8 (en)	2008-01-23
CN1420779A (zh)	2003-05-28
EP1257281A4 (en)	2003-03-19
CA2395854A1 (en)	2001-08-23
NZ521390A (en)	2004-05-28
RU2002120483A (ru)	2004-01-27
ES2295148T3 (es)	2008-04-16
EP1278528A4 (en)	2003-03-19
JP5253204B2 (ja)	2013-07-31
EP1813278B9 (en)	2015-04-01
PL200140B1 (pl)	2008-12-31
NO20023855D0 (no)	2002-08-14
EP1813278A1 (en)	2007-08-01
JP2004510691A (ja)	2004-04-08
MXPA02007931A (es)	2004-10-15
EP1813278B1 (en)	2014-10-29
PL357945A1 (en)	2004-08-09
IL150990A (en)	2009-05-04
US6455508B1 (en)	2002-09-24
EP1257281B1 (en)	2007-11-07
JP2004509061A (ja)	2004-03-25
SK287765B6 (sk)	2011-09-05
HUP0300027A2 (en)	2003-05-28
JP4975930B2 (ja)	2012-07-11

Publication	Publication Date	Title
DK1257281T3 (da)	2008-01-14	Nukleosidanaloger med carboxamidin-modificeret monocyklisk base
MY128463A (en)	2007-02-28	4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
EE02995B1 (et)	1997-06-16	1,3-oksatiolaannukleosiidi analoogide kasutamine hepatiit B ravimpreparaatide valmistamiseks
WO2003051306A3 (en)	2003-12-18	N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
BG108439A (en)	2005-03-31	4'-substituted nucleosides
NZ609146A (en)	2014-08-29	Modified 4’-nucleosides as antiviral agents
NZ610715A (en)	2014-07-25	Antiviral compounds and methods
IL152934A (en)	2010-12-30	Use of a nucleoside in the manufacture of a medicament for treating heapatitis c virus
JP2004509061A5 (da)	2006-01-05
AP1771A (en)	2007-08-23	3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
IL198610A0 (en)	2010-02-17	Chemical compounds
EA200701869A1 (ru)	2008-02-28	Пептидомиметические ингибиторы протеазы
JO2403B1 (en)	2007-06-17	Nickeloside derivatives antiviral
DE60215157D1 (de)	2006-11-16	Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
DK1115420T3 (da)	2002-11-04	Behandling af hepatitis B med thymosin-alpha-1 og lamivudin
MX9202634A (es)	1994-01-31	Uso de analogos de nucleosido de 1,3-oxatiolano en el tratamiento de hepatitis b.
DE60104288D1 (de)	2004-08-19	Antivirale therapie
TH65849A (th)	2004-12-27	สารตั้งต้นยา-3' ของ 2'- ดีออกซี- เบตา-l-นิวคลีโอไซด์